Acute graft-versus-host disease (GVHD) remains the major obstacle to a more favorable therapeutic outcome of allogeneic hematopoietic stem cell transplantation (HSCT). GVHD is characterized by tissue damage in gut, liver 
Introduction
Acute graft-versus-host disease (GVHD) is a potentially lethal complication in patients undergoing allogeneic hemopoietic stem cell transplantation (HSCT). It is characterized by damage of epithelial surfaces in target organs caused by alloactivated T-cells recognizing host tissue antigens. The severity of GVHD is determined by many factors, including the level of immunogenic disparity, 1 the Tcell dose, 2 the conditioning regimen 3 and the degree of immunosuppression. 4 A common feature of the primary GVHD target tissues is their exposure to microbes and microbial products through the epidermis, intestinal mucosa and portal circulation. The significance of the intestinal microbial flora for the pathogenesis of GVHD was first discovered in experimental mouse models and confirmed in human trials in the 1970s. 5, 6 Based on these findings it became common practice to perform intestinal decontamination by means of orally administered antibiotics in patients undergoing allogeneic HSCT. Despite a large body of data providing evidence that microbes or microbial products (PAMPs) interact with innate receptors (pathogen recognition receptors, PRRs), on hematopoietic cells, mucosal cells and endothelial cells, it took until the mid 1990s before the first PRR was discovered: In 1996 the PRR 'Toll', was discovered and determined to be responsible for innate immune responses to
Aspergillus fumigatus in Drosophila. 7 Shortly after this publication the human homologue of 'Toll' was defined and named Toll-like receptor (TLR) and later on TLR4. 8 From this point research in the field of innate immunity has increased substantially and to date hundreds of receptors, proteins and small molecules, which are involved in anti-microbial immunity as well as inflammatory disorders, have been discovered.
Mucosal surfaces and vascular endothelium, the potential sites of pathogen entry, are rich in resident innate immune cells, such as macrophages and dendritic cells (DC's). 9 Signaling through PRRs regulate the activity of DCs, leading to phagocytosis, chemokine receptor expression, cytokine secretion, migration from peripheral tissue to draining lymph nodes and antigen 
The intestinal microflora during GVHD
Early studies in allogeneic mouse radiation chimeras showed that the mortality due to the 'secondary disease' -later called GVHD -is significantly reduced in germfree mice or when decontamination of the gut flora was performed. One or two polymorphisms were detected in about 10% of patients and donors.
The authors found a trend towards a reduced incidence of grade II to IV acute GVHD when a TLR4 polymorphism was present (33% vs. 47%) but failed to detect statistically significant results. They concluded that a much larger study population would be needed to confirm the role of LPS and TLR4 in the pathogenesis of GVHD in humans. Interestingly, in a subsequent study Elmaagacli and coworkers also found no correlation of the presence of TLR4 polymorphisms to the overall incidence of GVHD in a mixed cohort of 307 HSCTs from HLA-identical siblings and matched unrelated donors (MUD).
53 Surprisingly, they found that the severity GVHD was significantly increased in a univariate analysis if one TLR4 polymorphism (Thr-399Ile) was present in both and recipient of an allo-HSCT as compared with wild type donor/recipient pairs (42% vs. 15% severe GVHD). However, the TLR-4 polymorphism failed to influence the occurrence of severe GVHD in the multivariate analysis indicating that its role might not be very pronounced, which is in line with the data of Lorenz et al. on GVHD depending on the timing of administration. When 3M-011 was given after allo-BMT the GVHD-related mortality rate was increased from 0% to 50% in a major mismatched model. 55 In a subsequent work the same group demonstrated, however, that pretreatment (prior to allo-BMT) with the same TLR7/8 agonist significantly delayed GVHD lethality and reduced GVHD target organ injury.
56
Interestingly, pretreatment with 3M-011 resulted in increased levels of the immunosuppressive intracellular enzyme indoleamine 2,3-dioxygenase (IDO), which plays a crucial role in GVHD regulation.
56,57
Collectively these data suggest that detection of pathogens (viral DNA and RNA)
by TLR7 can lead to localized and systemic inflammation as well as to inhibition of inflammation during GVHD.
In a murine GVHD model Balsari and colleagues demonstrated reduced systemic GVHD leading to improved survival in TLR9-/-allo-BMT recipients. 
NOD-like receptors (NLRs) during GVHD
NOD2 is the best studied NLR during GVHD. NOD2 (CARD15) detects muramyl dipeptide (MDP), a molecule that is produced during the synthesis and degradation of peptidoglycan, which is a cell wall component of most bacteria.
Single nucleotide polymorphisms (SNPs) near, or within, the NOD2 LRR region (G908R, L1007insC and R702W) are present in about 15% of the population and constitute genetic risk factors for the development of Crohn's disease. 61, 62 In addition, polymorphisms in the NACHT region of NOD2 are linked to other inflammatory diseases, such as Blau syndrome 63 and early onset sarcoidosis. 64 We performed studies in murine allo-BMT models to determine the role of NOD2 during GVHD. 65 We found that NOD2 deficiency of the allo-BMT donor (either donor T-cells or BM) has no significant impact on the development of GVHD and does not regulate allo-activation of donor T-cells. Our data suggest that NOD2 has no cell-intrinsic role in the regulation of T-cell activity during GVHD despite the increasing evidence that innate immune receptors can modulate T-cell function and activation during inflammation. [66] [67] [68] In NOD2-/-allo-BMT recipients we observed increased GVHD in both MHC-mismatched and MHC-matched models.
Using chimeric mice, we demonstrate that NOD2 deficiency in the hematopoietic system, but not in the non-hematopoietic system, aggravates both experimental GVHD as well as experimental TNBS colitis. We studied DCs of NOD2-/-alloFor personal use only. on October 31, 2017. by guest www.bloodjournal.org From BMT recipients and found increased activation and function leading to augmented proliferation as well as activation of allogeneic donor T-cells, which resulted in target organ damage. These data supports the hypothesis that NOD2 can negatively regulate the activity and function of host DCs, resulting in increased allo-activation and proliferation of donor T-cells in NOD2-/-allo-BMT recipients.
Our results suggest that loss of intestinal epithelial cell function causing impaired anti-bacterial resistance, which has been proposed as mechanism for increased inflammation in NOD2-/-mice, 69 is not responsible for the increased GVHD and first single center analysis and also in a subsequent multicenter study, we found an association between a higher incidence of GVHD and NOD2 SNPs of the donor or recipient. 75, 76 These associations were particularly strong in recipients of an HLA-identical sibling allograft, whereas only the donor L1007insC SNP predicted increased non-relapse mortality in recipients of an HLA-matched unrelated donor allograft. This difference could either reflect a higher baseline mortality following unrelated donor SCT or the higher frequency of both, donor and recipient SNPs in relatives. 77 Because the lung has also an extensive exposure to bacterial ligands, we tested the hypothesis that a defective inflammatory response might trigger allo-reactivity. In a large analysis of more than 400 patients, the cumulative incidence of bronchiolitis obliterans syndrome
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From was 23% in patients with NOD2 SNPs but only 1% in recipients without NOD2 SNPs. 78 Interestingly, Donnelly and coworkers confirmed the connection between NOD2 SNPs and GVHD in a smaller study on T-cell depleted allo-HSCT using the same SNPs (8, 12 and 13). 79 In contrast to the studies described previously other transplant centers could not find a significant impact of NOD2 SNPs on the incidence of GVHD.
Granell et al. reported that the NOD2 SNPs 8, 12 and 13 were not associated to acute or chronic GVHD, but still increased mortality due to pulmonary complications, in a small cohort of 85 patients receiving CD34-selected HLAidentical sibling transplants. 80 Saraifi et al. also found no significant impact of these NOD2 SNPs on incidence of acute GVHD in a series of 198 patients transplanted in Stockholm. 81 In a study by Marsh and coworkers in a similarly sized patient cohort the incidence of acute GVHD was low and there was no significant difference due to the presence of NOD2 SNPs (8, 12 and 13) but this trial focused on unrelated donor transplants receiving campath prophylaxis. 82 Steinbach and colleagues also found no significant impact of these three NOD2
SNPs on the incidence of GVHD in a cohort of 231 children, who underwent allo-HSCT. 83 The conflicting results between the different clinical studies on the role of NOD2 polymorphisms during GVHD are most likely explained by differences
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From between the study cohorts including the NOD2 SNP frequency, overall incidence of GVHD, T-cell depletion, type of conditioning regimen, intestinal microbial decontamination, donor source and environmental factors. In conclusion, it appears that polymorphisms in the NOD2 gene locus of the recipient can negatively influence survival post allogeneic HSCT. However, transplant specific strategies such as T-cell depletion or gut decontamination may alter the activation of dendritic cells or epithelial cells and the role of NOD2 in these processes. The effect of NOD2 SNPs of the allo-HSCT donor on the incidence of GVHD is controversial. Experimental data suggest that there is no major effect of NOD2 on the allo-HSCT donor side on the regulation of GVHD. 65 In addition, functional data on the impact of NOD2/CARD15 SNPs in humans are urgently needed: As shown for inflammatory bowel disease, peripheral blood mononuclear cells from recipients and donors with NOD2/CARD15 SNPs have a significantly decreased capacity to release IL8 following stimulation with the ligand MDP. 75, 77, 78, 84, 85 More recently, we observed a diminished recruitment of both, CD4 cells and neutrophils in intestinal biopsies from patients suffering from gastrointestinal GVHD indicating that NOD2/CARD15 may play a role in recruitment of these cells via chemokines released by APCs. 86 Based on these data, GVHD can be seen as an imbalance in protective CD4 cells which is further enhanced in the presence of NOD2/VCARD15 SNPs. 
Conclusions and future directions
Recent research has illuminated details as to how stimulation of innate immune receptors by microbial associated molecules significantly contribute to the inflammatory processes that consequently lead to recruitment of allo-activated Tcells as well as tissue damage in GVHD target organs. The inflammatory cascade that characterizes GVHD is initiated by PAMPs that activate PRR signaling in resident innate immune cells, epithelial cells and endothelial cells.
For 
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